LifeVantage Q2 revenue falls 27.8%, misses estimates

Overview

• Health and wellness firm's Q2 revenue fell 27.8%, missing analyst expectations

• Adjusted EPS for Q2 was $0.15, down from $0.22 a year ago

• Company announced a new $60 mln share repurchase program

Outlook

• LifeVantage expects fiscal 2026 revenue between $185 mln and $200 mln

• Company forecasts adjusted EBITDA of $15 mln to $19 mln for fiscal 2026

• LifeVantage projects adjusted EPS of $0.60 to $0.80 for fiscal 2026

Result Drivers

• GLP-1 SYSTEM CHALLENGES - Revenue decline driven by decreased sales of MindBody GLP-1 System as company cycled its launch

• LOVEBIOME OFFSET - Sales of LoveBiome product line partially offset revenue decline, acquired in October 2025

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for LifeVantage Corp is $14.50, about 170.5% above its February 3 closing price of $5.36

• The stock recently traded at 5 times the next 12-month earnings vs. a P/E of 8 three months ago

Press Release: ID:nGNX9HKBtL

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.